Scope: Tsodikov: Mechanistic and Pharmacologic Studies of Selective Mithramycin Analogues Targeting EWS-FLI1 in Ewing Sarcoma

Pharmacology, Toxicology and Pharmaceutical Science

1. Mithramycin 100%
2. Ewing Sarcoma 100%
3. Neoplasm 50%
4. Transcription Factors 37%
5. Pharmacokinetics 37%
6. Carcinogenesis 25%
7. Drug Development 12%
8. Clinical Trial 12%
9. Overall Survival 12%
10. Combination Therapy 12%
11. Cytotoxicity 12%
12. Microsatellite DNA 12%